Study summary

A targeted pill shrank tumors in people with NF2-related schwannomatosis, with meningiomas benefiting most

INTUITT-NF2 trial (brigatinib) · 40 people (20 with meningiomas), phase 2 · Published June 2024, New England Journal of Medicine

23%of all tumors shrank

What was tested

Brigatinib, a lung cancer pill, for people with NF2-related schwannomatosis (an inherited condition causing multiple meningiomas and nerve tumors) whose tumors were growing.

What they found

23% of all tumors shrank; meningiomas and non-vestibular schwannomas benefited most.
Tumor growth rates slowed for all tumor types.
Hearing improved in 35% of eligible ears.

What it means

The first platform trial for NF2-related tumors; other arms test more targeted drugs.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.